Compare Enveric Biosciences Inc (ENVB) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Grab Holdings Ltd. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Grab Holdings Ltd. trades at $3.13 (market cap $12.72B). The key difference: Grab Holdings Ltd. is far larger — about 1870.6× Enveric Biosciences Inc's market cap, and Grab Holdings Ltd. is more actively traded (65,352,859 versus 64,867). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Grab Holdings Ltd. for 94 Days on average.
| ENVB | GRAB | |
|---|---|---|
Market Cap | $6.80M | $12.72B |
Volume | 64,867 | 65,352,859 |
Sector | Health | Technology |
52-Week High | $10.80 | $6.17 |
52-Week Low | $1.27 | $2.80 |
Typical Hold Time | 14 Days | 94 Days |
Enterprise Value | -$1.49M | $8.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
GRAB trades at $3.08, up 0.33% with bearish technical signals but strong fundamentals. The company achieved profitability in 2025 with $268M net income and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $30M CEO share purchase and acquisition of Atome Financial, signaling management confidence and financial services expansion.
GRAB presents a turnaround story with improving profitability and analyst support (91.7% buy ratings), though technical indicators remain bearish. Key risks include aggressive capital deployment and regional regulatory challenges. The stock offers growth potential but requires monitoring of execution risks and competitive pressures in Southeast Asia.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
